Zhejiang Medicine Co., Ltd. (SHA:600216)

Market Cap	12.99B
Revenue (ttm)	9.38B
Net Income (ttm)	1.16B
Shares Out	961.64M
EPS (ttm)	1.21
PE Ratio	11.17
Forward PE	10.10
Dividend	0.15 (1.09%)
Ex-Dividend Date	Jul 10, 2024

Volume	30,828,504
Average Volume	21,983,006
Open	13.51
Previous Close	13.51
Day's Range	13.51 - 13.96
52-Week Range	9.47 - 19.40
Beta	0.63
RSI	49.59
Earnings Date	Apr 24, 2025

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceutical products in China. The company products include synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company provides injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin products....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 6,227
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2024, Zhejiang Medicine's revenue was 9.38 billion, an increase of 20.29% compared to the previous year's 7.79 billion. Earnings were 1.16 billion, an increase of 170.11%.